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Inhibition of monocyte chemoattractant protein-1 expression eases lead to tubulointerstitial alterations such as intersti-
in tubular epithelium attenuates tubulointerstitial alteration in tial cell infiltration, tubular atrophy, and fibrosis [4–7].
rat Goodpasture syndrome. An initial event of progressive interstitial alterations in
Background. To examine the role of monocyte chemoattrac-
most experimental models of renal diseases is monocytetant protein-1 (MCP-1) expressed by tubular epithelium in
infiltration into the interstitial compartment [5, 6, 8, 9].tubulointerstitial alterations in situ, the level of MCP-1 mRNA
in tubular epithelium was lowered selectively in the rat model Monocyte/macrophages play a role as antigen-presenting
of Goodpasture syndrome (GPS). cells in the immunologic process [10] and are the main
Methods. Intravenously administered antisense oligodeoxy- source of a number of humoral mediators, including
nucleotide (ODN) is taken up by renal tubular epithelium and
transforming growth factor-b (TGF-b), at sites of in-has been found to block expression of target genes in rats.
flammation. TGF-b is one of the key cytokines contribut-MCP-1 antisense ODN was injected into GPS rats every second
ing to renal fibrosis, resulting in a permanent loss ofday from days 27 to 35 after immunization (this represents
the time when renal MCP-1 mRNA level was increased and renal function [5, 11, 12]. Thus, the C-C chemokines, for
interstitial mononuclear cell infiltration was aggravated). example, monocyte chemoattractant protein-1 (MCP-1),
Results. In addition to a reduction in the level of tubular macrophage inflammatory protein-1a (MIP-1a), andMCP-1 mRNA, antisense ODN treatment attenuated mono-
RANTES, which preferentially recruit monocytes intocyte infiltration significantly and preserved renal function in
the extravascular interstitium, have been examined in-GPS rats. However, ODN injection did not affect glomerular
MCP-1 expression and glomerular histopathology, and there tensively [7, 13, 14].
were no significant changes in the urinary protein excretion In this study, we have focused on the role of MCP-1
rate. as a chemoattractant for monocyte, T lymphocyte, and
Conclusion. Our findings provide direct evidence that natural killer (NK) cells [15]. MCP-1 appears to contrib-MCP-1, expressed by tubular epithelium, plays a pivotal role
ute to the inflammatory component of human diseases,in mediating secondary tubulointerstitial alterations in the GPS
including atherosclerosis, multiple sclerosis, or rheuma-model.
toid arthritis [15]. Mice with targeted deletions of the C-C
chemokine receptor 2, the receptor for MCP-1, exhibited
impaired monocyte migration to sites of inflammationIn human glomerular disease, several investigators
[16]. In contrast, enforced expression of MCP-1 couldhave found that the secondary renal tubulointerstitial
induce controlled recruitment of monocytes to specificalterations correlate better with renal function and dis-
organs [17, 18]. In the kidney, a marked up-regulationease prognosis than the glomerular alteration itself [1–3].
of MCP-1 was demonstrated not only in glomerular cellsHowever, it remains unknown as to how glomerular dis-
but also in tubular epithelial cells in human and experi-
mental nephritis. The up-regulation of MCP-1 was asso-
ciated closely with monocyte accumulation [7, 19, 20]. InKey words: antisense oligodeoxynucleotide, monocyte infiltration, cre-
atinine clearance, proteinuria. more direct studies, cultured proximal tubular epithelial
cells were induced to synthesize MCP-1 by treatmentReceived for publication February 2, 1999
with interleukin-1b (IL-1b) and tumor necrosis factor-aand in revised form September 29, 1999
Accepted for publication October 11, 1999 (TNF-a) or urinary protein [21, 22], suggesting that this
chemokine might be involved in mediating interstitialÓ 2000 by the International Society of Nephrology
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alterations. However, there is little definitive evidence with TNF-a (R&D Systems, Minneapolis, MN, USA) at
10 ng/mL in 0.5% fetal calf serum (FCS) media wasfor a role of MCP-1 in mediating the accumulation of
monocytes in tubulointerstitial diseases [4, 6, 7]. carried out for four hours [21]. Untreated cells were
permeabilized with SL-O without ODN treatment andSeveral investigators have shown that anti–MCP-1 an-
tibodies inhibit the progression of glomerular damage stimulated with TNF-a, and the control cells were also
permeabilized with SL-O without ODN treatment andand proteinuria in nephrotoxic nephritis [23–26]. In addi-
tion, others have investigated the effects of anti–MCP-1 without stimulation by TNF-a.
antibodies on interstitial leukocytes [25]. This study
Northern blot and reverse transcription-polymeraseshowed that in mice, MCP-1 was more important than
chain reaction analysisRANTES in the induction of glomerular crescent forma-
tion and interstitial fibrogenesis in nephrotoxic nephritis Total RNA was extracted from culture cells, whole
kidneys, or glomeruli isolated by a sieving method, using[25]. However, it remains unclear whether the effects on
the interstitium are due to either the direct interaction TRIzole (GIBCO BRL, Grand Island, NY, USA) ac-
cording to the manufacturer’s instructions. Murine JEof the antibody with MCP-1 expressed by tubular epithe-
lium or the beneficial actions of the antibody on glomeru- (MCP-1) cDNA (628 bp; the exon parts in the sequence
1508/12207 of murine JE gene; Genbank, accession no.lar damage with subsequent effects on the tubulointer-
stitium. M19681) was obtained by reverse transcription-polymer-
ase chain reaction (RT-PCR) and subcloned into pGEM-Recently, oligodeoxynucleotides (ODNs), adminis-
tered into the systemic circulation, have been demon- 7Zf(1) (Promega, Madison, WI, USA). MCP-1 cDNA
and GAPDH cDNA were labeled with random primersstrated to be selectively taken up by renal tubular epithe-
lial cells in mice and rats [27, 28]. Proximal tubular and 32PdCTP and were used as probes. Northern blotting
was carried out as reported previously [32].epithelial cells are thought to take up ODNs efficiently,
without detectable degradation, through the activity of The GeneAmp RNA PCR Kit (Perkin-Elmer Cetus,
Norwalk, CT, USA) was used for cDNA synthesis andODN-binding proteins on the brush border membrane
[28]. Based on these findings, Noiri et al reported that PCR amplification, following the method of Wang et al
[22]. The primers for MCP-1, sense primer, 59-TATGantisense ODN for inducible nitric oxide synthetase
(iNOS) attenuated NO production in renal epithelium, CAGGTCTCTGTCACGC-39, and antisense primer, 59-
AAGTGTTGAACCAGGATTCACA-39, were used toavoiding exacerbation of postischemic acute renal failure
[29]. Our preliminary studies have shown that in vivo, amplify a 595 bp sequence in combination with primers
for the housekeeping gene GAPDH yielding 520 bp. TheMCP-1 antisense ODN is selectively taken up by proxi-
mal tubular epithelial cells and results in decreased primers for GAPDH were 59-AATGCATCCTGCAC
CACCAA-39 as the sense primer, and 59-GTAGCCAMCP-1 mRNA levels. To test whether MCP-1 expression
by tubular epithelium induces accumulation of mono- TATTCATTGTCATA-39 as the antisense primer. Lin-
earity of the amplification, in some experiments, wascytes in the interstitium, we repeatedly injected MCP-1
antisense ODN into Goodpasture syndrome (GPS) rats. verified by the use of serial quantities of both template
and cycles of PCR. PCR was carried out for 30 cycles
in this study.
METHODS
Quantitative densitometry was performed on autora-
Oligodeoxynucleotide application to cultured renal diograms of Northern blot analysis using a computer-
tubular epithelial cells by streptolysin-O based measurement system (Mac SCOPE, ver. 2.5; Mi-
permeabilization tani Corp., Hukui, Japan). The expression of the MCP-1
gene was corrected by dividing the signal density by thatPhosphorothioate-capped ODNs were synthesized by
an automated synthesizer. The MCP-1 sense ODN se- obtained for GAPDH.
quence comprised 59-ACCACTATGCAGGTCTCT-39.
Animal manipulation and experimental protocolsThe antisense ODN sequence comprised 59-AGAGACC
TGCATAGTGGT-39, and the mutated antisense ODN Male Wistar rats (160 to 200 g) were purchased from
Clea Japan (Tokyo, Japan). Animal care and treatmentsequence comprised 59-ACACAGGTCGATACTCC
T-39; these sequences were chosen from the rat MCP-1 conformed to the institutional guidelines. To generate
GPS in rats, rats were immunized with 25 mg of a3(IV)gene [30]. A rat renal proximal tubular epithelial cell line,
RPTC (kindly provided by Dr. J. Ingelfinger, Harvard NC1 domains as reported previously [33, 34]. Initially,
to characterize GPS rats, daily urinary protein excretion,Medical School), was used in this study, and the method
for streptolysin-O (SL-O; Sigma, St. Louis, MO, USA) renal histopathology, and MCP-1 expression were moni-
tored for two months. In addition, to visualize the distri-permeabilization was essentially that of Spiller et al [31].
After confirmation of attachment of ODN-treated bution of ODN and the effects of antisense ODN, FITC-
conjugated ODN, MCP-1 sense, and antisense ODNsRPTC cells to the bottom of the culture dish, stimulation
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Fig. 1. Characterization of kidneys of Goodpasture syndrome (GPS) rats. (a) Day 28. Crescent formation was observed in some glomeruli, but no
significant interstitial mononuclear cell infiltration was seen (HE stain, 3200). (b) Day 35. Prominent mononuclear cell infiltration in the interstitium
appeared in parallel to the progression of glomerular and tubular damage (HE stain, 3200). (c) monocyte chemoattractant protein-1 (MCP-1) mRNA
expression in the kidneys. Northern blot analysis with total RNA extracted from whole nephritic kidneys revealed that MCP-1 mRNA began to
increase on day 21 and reached a peak level on day 35. A representative blot selected from three separate experiments is shown. (d) MCP-1 protein
expression on day 28. MCP-1 is located in the glomeruli and in the tubular epithelium (3200).
were injected intravenously at a concentration of 1.0 On day 36, rats from each group were placed in metabolic
cages for 24 hours to collect urine. Kidney tissues andmg/kg into day 27 GPS rats. Day 27 was selected because
a significant increase in the MCP-1 expression was found blood samples were collected from each rat at the time
of sacrifice on day 37. One kidney was used for RNAin GPS rat kidney on day 28. The dose of ODN (1.0
mg/kg) was determined based on the report by Noiri et and protein extraction. Tissues from the other kidney
were fixed in 4% paraformaldehyde in phosphate-buf-al [29], and its efficacy was reconfirmed by the observa-
tion that FITC-conjugated ODN injected intravenously fered saline (PBS) overnight. One half of each fixed
tissue was processed into paraffin blocks for histopathol-at the relevant dose was accumulated in the tubular epi-
thelium of normal rats and day 28 GPS rats (described ogy and immunohistochemistry. The other half was
rinsed in serial concentrations of sucrose solutions andlater in this article). The experimental groups of the
present study include MCP-1 antisense ODN-treated then snap frozen for immunolocalization and in situ hy-
bridization.GPS rats (MCP-1-AS, N 5 6), MCP-1 sense ODN-
treated GPS rats (MCP-1-S, N 5 6), untreated GPS rats
Histopathology, immunohistochemistry(untreated, N 5 6), and control normal rats (N 5 4).
and immunolocalizationOn days 27, 29, 31, 33, and 35, either sense or antisense
ODNs were injected intravenously at a concentration Four micrometer paraffin sections were stained with
hematoxylin and eosin (HE). Glomerular hypercellular-of 1 mg/kg. The interval between each injection was
determined based on our finding that FITC-conjugated ity and interstitial mononuclear cell infiltration were
quantitatively evaluated with a computer-assisted imageODN remained in the kidney 24 hours after injection.
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Fig. 2. Monocyte chemoattractant protein-1 (MCP-1) antisense oligodeoxynucleotide (ODN) application in vitro. (A) Northern blot analysis of
MCP-1 mRNA in RPTC cells treated with antisense ODN. (B) Quantitative densitometric analysis of (A). Antisense ODN significantly lowered the
MCP-1 mRNA level (lane 4 in A, column 4 in B) in relationship to the control level (lane 5 in A, column 5 in B). However, sense ODN-treated,
mutated antisense ODN-treated and untreated RPTC cells strongly express MCP-1 mRNA (lanes 1 through 3, columns 1 through 3, respectively).
A representative blot from three separate experiments is shown; densitometric data were obtained from all three blots.
analysis system (Mac SCOPE) in 30 glomeruli and 30 marker [35] and were observed by confocal microscopy
high-power (3200) cortical fields, respectively. Each his- (MRC600; Bio-Rad, Hercules, CA, USA). Negative con-
topathological index was calculated as the mean cell trols for immunostaining consisted of replacing each of
number per 10 glomeruli or one high-power cortical field. the primary antibodies with equivalent concentrations
Immunohistochemistry was carried out according to the of rabbit or murine IgG.
method reported previously [32] with a slight modifica-
tion. In this study, the deparaffin sections were boiled Western blot analysis
in citrate buffer under microwave in addition to the treat-
Kidney tissues were sonicated in cold RIPA lysisment with proteinase K for unmasking antigenicity. Rab-
buffer [1% NP40, 0.1% sodium dodecyl sulfate (SDS),bit antiserum to rat MCP-1 (obtained from Pepro Tech,
100 mg/mL phenylmethylsulfonylfluoride, 0.5% sodiumLondon, UK) was used as the primary antibodies to
deoxycholate, 1 mmol/L sodium orthovanadate, 2 mg/mLdetect MCP-1. Biotinylated goat antirabbit IgG (Ameri-
aprotinin, 2 mg/mL antipain, and 2 mg/mL leupeptin incan Qualex, LaMirada, CA, USA) was then applied as
PBS], and the homogenates were centrifuged for fivethe secondary antibodies. For immunolocalization, 4 mm
minutes at 48C. Protein concentration of the supernatantfrozen sections were reacted with a murine monoclonal
antirat monocyte/macrophage antibody, ED-1 (Serotec, was determined using a bicinchoninic acid (BCA) pro-
Oxford, UK), to detect monocytes/macrophages. Then tein assay kit (Pierce, Rockford, IL, USA), and then 30
the sections were reacted with FITC-conjugated goat mg of proteins were examined as described previously
antimouse IgG (American Qualex) and analyzed by flu- with rabbit anti–MCP-1 [32].
orescent microscopy. ED-1–positive monocyte/macro-
phages in the glomeruli and the interstitium were In situ hybridization
counted as described earlier in this article. Sections of
Monocyte chemoattractant protein-1 mRNA tran-renal tissues from rats injected with FITC-conjugated
scripts were detected in paraformaldehyde-fixed, frozenODN were observed directly with fluorescent micros-
tissues by in situ hybridization with MCP-1 cRNA probescopy. Additionally, to localize the distribution of ODN,
generated from the mouse MCP-1 cDNA according tothe same sections were stained with TRITC-conjugated
the method of Hirota et al [36]. Hybridization was carriedTetra-gon-olobus purpureas (Sigma) as the proximal tu-
out at 458C for 16 hours, and the final washing was inbular epithelium marker or with TRITC-conjugated Ar-
achis hypogaea (Sigma) as the distal tubular epithelial 0.2 3 standard saline citrate for 15 minutes at 608C.
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Fig. 3. Distribution of FITC-conjugated ODN in the kidney at 12 hours after intravenous injection. (a) Normal kidney. FITC-conjugated ODN was
observed in the tubular epithelium (3300). (b) Nephritic kidney of GPS rats on day 28. FITC-conjugated ODN was taken up by the tubular epithelium,
and its distribution was substantially the same as in the normal kidney (3300). (c) The autofluorescence of nephritic kidney was negligible (3300).
(d) Dual staining with TRITC-conjugated Tetragonolobus purpureas (TP) as a proximal tubular epithelium marker. FITC-conjugated ODN (in green)
colocalized with TP (in orange) in the proximal tubular epithelium, yielding a yellow color and indicating that ODN was taken up by proximal tubular
epithelial cells exclusively. TP, only, localized to the glomeruli, yielding an orange color (3300).
Urinary protein and renal function RESULTS AND DISCUSSION
Blood and 24-hour urine collections were taken on Characterization of Goodpasture syndrome rats and
day 37 prior to sacrifice. Urinary protein was measured expression of monocyte chemoattractant protein-1 in
using a BCA protein assay kit (Pierce). Concentrations the nephritic kidneys
of serum and urine creatinine were determined using As others have reported [33], we found that when rats
the standard Jaffe rate reaction (alkaline picrate; Sigma). were immunized with a3(IV) NC1 domains, they devel-
Urine volume was measured gravimetrically, and urine oped significant proteinuria on day 21 that increased to
flow rate was factored per gram body weight. Creatinine
a peak level at approximately day 35 (data not shown).clearance (CCr) was calculated as the ratio of the urine/ Rat IgG was found distributed linearly along glomerularplasma concentration of creatinine multiplied by the
basement membranes by day 14, and focal crescentic glo-urine flow rate. Urinary protein excretion rate was calcu-
merulonephritis with marked glomerular hypercellularitylated as the ratio of urinary protein per min/CCr to ex-
was observed on day 28 (Fig. 1a). Crescent formation include the influence of CCr on the glomerular protein traf-
the glomeruli became more apparent, and tubulointersti-ficking, resulting in an indicator of glomerular damage.
tial alterations with peritubular mononuclear cell infiltra-
Data analysis tion became detectable on day 35 (Fig. 1b). In parallel to
peritubular mononuclear cell infiltration, MCP-1 mRNAValues were presented as mean 6 SE. Statistical differ-
expression across the entire nephritic kidney was signifi-ences between groups were evaluated by analysis of vari-
cantly up-regulated from day 21 and increased to a peakance, followed by Duncan’s multiple range test [37], with
P , 0.05 used as the requirement for significance. level on day 35 (Fig. 1 c, d). MCP-1 protein was found
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Fig. 4. MCP-1 antisense ODN application in vivo. (A) Northern analysis
of total RNA extracted from whole nephritic kidneys at 12 hours after
the administration of ODN on day 28. (B) Quantitative densitometric
analysis of (A). MCP-1 antisense ODN reduced the MCP-1 mRNA to
control levels (lanes 3 and 4 in A, columns 3 and 4 in B). MCP-1 mRNA
levels in the kidneys of sense ODN-treated GPS rats (lane 2 in A, column
2 in B) were similar to the untreated GPS rats (lane 1 in A, column 1
in B). A representative blot selected from four separate experiments is
shown, and the densitometric data were obtained from these four blots.
(C) RT-PCR detection of MCP-1 mRNA in the glomeruli isolated by
serial sieving. The glomerular MCP-1 mRNA level was increased in the
untreated GPS rats on day 28 when compared with the control rats (lanes
4 and 1). MCP-1 antisense or sense ODN did not affect the increased
level of MCP-1 mRNA in the glomeruli (lanes 2–4). These are the
representative data selected from three separate experiments.
not only in the glomeruli but also in the tubular epithelium epithelium, FITC-conjugated ODN was injected intrave-
on day 28 (Fig. 1e), which is consistent with findings in nously into normal rats and day 27 GPS rats at a concentra-
other experimental models and in human nephritis [7, 19, tion of 1 mg/kg. Kidneys were harvested and evaluated
20]. Some humoral factors, including IL-1b, TNF-a [21], at 12, 24, and 48 hours after injection. The kidneys showed
and urinary protein [22], directly or indirectly enhance remarkable accumulation of ODN in the tubular epithe-
MCP-1 mRNA expression in tubular epithelium. Al- lium at 12 hours after injection (Fig. 3 a, b). Detectable
though the exact regulation of tubular MCP-1 expression ODN remained there for as long as 24 hours and subse-
in GPS remains unclear, most of these factors prevail quently disappeared 48 hours later (data not shown).
ubiquitously and are likely to induce MCP-1 and other FITC-conjugated ODN colocalized exclusively with the
downstream members of proinflammatory cascade in this proximal tubular epithelial marker, Tetragonolobus pur-
model [4–9, 14]. pureas (Fig. 3d), but not with the distal tubular epithelial
marker, Arachis hypopaea (data not shown). Administra-Application of MCP-1 antisense ODN in vivo and its
tion of MCP-1 sense ODN had no effect, but MCP-1effects on Goodpasture syndrome rats
antisense ODN lowered the MCP-1 mRNA level in wholeConsistent with other studies [21], we found that TNF-a
nephritic kidney from day 28 GPS rats at 12 hours after(10 ng/mL) stimulates RPTC cells to express MCP-1
injection (Fig. 4 A, B). RT-PCR revealed that the levelmRNA. TNF-a–induced MCP-1 mRNA expression
of MCP-1 mRNA in the glomeruli of day 28 GPS ratsreached a peak level within four hours. Treatment of SL-O
was increased when compared with those of control rats.permeabilized RPTC cells with MCP-1 antisense ODN
In addition, neither antisense nor sense ODNs affectedafter four hours of incubation with TNF-a prevented the
the glomerular MCP-1 mRNA level (Fig. 4C). These re-increase in MCP-1 mRNA expression (Fig. 2). Sense ODN
sults show that ODNs were selectively taken up by tubularand mutated antisense ODN treatments produced no sig-
epithelial cells in the nephritic kidney and suggest thatnificant effects (Fig. 2). This result demonstrated that the
MCP-1 antisense ODN lowered MCP-1 mRNA expres-sequence employed as MCP-1 antisense was effective.
To demonstrate the delivery of ODN into renal tubular sion in tubular epithelium in vivo.
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Fig. 5. MCP-1 protein and mRNA expression in the kidney of GPS rats on day 37 after multiple injections of MCP-1 antisense ODN. (a) MCP-1
protein expression in the kidney of MCP-1-S rats. MCP-1 protein persisted in the tubular epithelium of the MCP-1-S rats (3200). (b) MCP-1 protein
expression in the kidney of the MCP-1-AS group. The MCP-1 protein level was reduced in the tubular epithelium (3200). (c) In situ hybridization
analysis of MCP-1 mRNA expression in the kidney of sense ODN-treated GPS rats on day 37. Using MCP-1 antisense probe, MCP-1 mRNA was
detected in the tubular epithelium (arrows) and faintly in the glomeruli (3300). (d) The MCP-1 mRNA level in the kidney of antisense ODN-treated
GPS rats on day 37. MCP-1 mRNA was not found in the tubular epithelium of these rats (3300). (e) In situ hybridization using the MCP-1 sense
probe did not label the kidney of sense ODN-treated GPS rats on day 37 (3300). ( f) Western blot analysis of protein extracts from the kidneys of
ODN-treated GPS rats on day 37. The MCP-1 protein level was increased in the kidney of untreated animals, and the increased levels were not
affected by treatment with sense ODN in the MCP-1-S rats. However, MCP-1 protein was not detected in the sample of the MCP-1-AS group and
the control rats, suggesting that antisense ODN lowered MCP-1 protein expression in the nephritic kidneys.
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Fig. 6. Renal histopathology of GPS rats on day 37 after repeated injections of MCP-1 antisense ODN. (a) Renal histology of the MCP-1-S rats.
Remarkable glomerular and interstitial alterations were observed (HE stain, 3300). (b) Renal histology of the MCP-1-AS rats. Despite extensive
glomerular damage, interstitial mononuclear cell infiltration was significantly attenuated (HE stain, 3300). (c) Glomerular hypercellularity and
interstitial mononuclear cell infiltration index [mean cell number/10 glomeruli, and mean cell number/high-power (3200) cortical field, respectively].
Symbols are: (j) glomeruli; ( ) interstitium. No significant effects on glomerular hypercellularity were seen in either the MCP-1-AS or MCP-1-S
rats when compared with the untreated rats. However, the number of mononuclear cells in the interstitium was significantly lower in the MCP-1-AS
group than in either the MCP-1-S or untreated groups. (d) ED-1–positive monocyte/macrophages in the kidney of the MCP-1-S group. A number
of ED-1–positive monocyte/macrophages were seen in the glomeruli and the interstitium (3300). (e) ED-1–positive monocyte/macrophages in the
kidney of the MCP-1-AS group. The number of ED-1–positive monocyte/macrophages in the interstitium was significantly reduced (3300). ( f) ED-
1–positive monocyte/macrophage counts in the glomeruli (j) and the interstitium ( ) [mean ED-1 (1) cell number/10 glomeruli, and mean ED-1
(1) cell number/high-power (3200) cortical field, respectively]. Although the numbers of ED-1–positive monocyte/macrophages in the glomeruli
were not different between the MCP-1-S and MCP-1-AS rats, the numbers of ED-1–positive monocyte/macrophages in the interstitium of the MCP-
1-AS group were significantly lower than those of the MCP-1-S and untreated groups.
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Fig. 7. Renal functional parameters of GPS rats on day 37 after multiple injections of MCP-1 antisense ODN. (a) Urinary protein excretion rate.
Urinary protein excretion rate was not affected in either the MCP-1-AS or MCP-1-S groups when compared with the untreated group. (b) Creatinine
clearance (CCr). The decrease in CCr of the MCP-1-AS group was significantly suppressed compared with the untreated and MCP-1-S groups.
Modification of renal deterioration in Goodpasture that an absence of MCP-1 expression in the kidney results
in a reduction of tubular injury and macrophage-inducedsyndrome rats
interstitial inflammation in spite of obvious glomerularAfter multiple injection of ODNs between days 27 and
injury and proteinuria [38]. Although there are two sig-35, examination of MCP-1-S rats on day 37 revealed strong
nificant differences between their study and ours, theexpression of MCP-1 protein and mRNA in the tubular
means to accomplish a reduction of MCP-1 expressionepithelium (Fig. 5 a, c, f). Expression levels were similar
and the model used, both studies provide direct evidenceto those found in the control group. However, MCP-1
that MCP-1, expressed by tubular epithelium, has a pivotalprotein and mRNA expression in MCP-1-AS rats were
role in mediating monocyte infiltration into the intersti-significantly attenuated (Fig. 5 b, d, f). Although the glo-
tium when secondary to glomerular diseases. Therefore,merular hypercellularity in all three experimental groups
blocking MCP-1 expression in tubular epithelium may beprogressed to a similar degree (Fig. 6 a–c), aggravation
appropriate to treat some forms of human kidney disease.of the interstitial mononuclear cell infiltration in the MCP-
1-AS group was significantly attenuated compared with
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